Stephen T. Isaacs
Stephen T. Isaacs has served as our Chairman, President and Chief Executive Officer since 2008. Prior to Aduro, in 1991, Mr. Isaacs founded Cerus Corporation, a biomedical products company that commercialized the Intercept Blood Systems. He served as President and Chief Executive Officer of Cerus from 1991 to 2004. Prior to Cerus, Mr. Isaacs founded and served as Chief Executive Officer and President of HRI Associates and HRI Research, both biotechnology companies focusing on research and development. He held a non-teaching faculty position in the Department of Chemistry at the University of California Berkeley from 1978 to 1986. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents. Mr. Isaacs holds a B.A. degree in Biochemistry from University of California Berkeley, and had graduate training in organic chemistry in the Ph.D. program in the Department of Chemistry at Berkeley.
Gerald Chan, D.Sc.
Dr. Gerald Chan has served on our board of directors since 2014. Dr. Chan co-founded the Morningside group, a private investment group with venture, private equity and property investments, in 1986. He has served as a member of the Global Advisory Council of the International Society for Stem Cell Research since 2008, the Global Advisory Council of Harvard University since 2012, the Dean’s Board of Advisors of the Harvard School of Public Health since 2011, the advisory boards of the Cold Spring Harbor Conferences Asia since 2008, the Johns Hopkins Nanjing Center since 2004 and the Columbia University Center for Radiological Research since 2010. Dr. Chan also has been a member of the board of directors of Hang Lung Group Limited since 1986. Dr. Chan received his B.S. and M.S. degrees in engineering from the University of California, Los Angeles, and his Master’s degree in medical radiological physics and Doctor of Science degree in radiation biology from Harvard University. He did his post-doctoral training at the Dana-Farber Cancer Institute as a fellow of the Leukemia Society of America.
William M. Greenman
William M. Greenman has served as a member of our board of directors since 2010. Mr. Greenman is currently the President and Chief Executive Officer of Cerus Corporation, and has held several executive and management positions with Cerus since joining the company in 1995. Prior to Cerus, he worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman holds undergraduate degrees in Biological Sciences and Economics from Stanford University.
Ross Haghighat has served as a member of our board of directors since 2009. Mr. Haghighat is the founder, Chairman and Managing Partner of Triton Systems, Inc. Additionally, Mr. Haghighat has served on the board of directors of S12 Technologies and FRX Polymers since 2009. Mr. Haghighat holds a B.S. and a Masters in Material Science, Organometallic Chemistry from Rutgers University and a Master of Business Administration from Boston College.
Frank McCormick, Ph.D., F.R.S., D.Sc.
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has served as a member of our board of directors since 2010 and is a member of the board’s Science and Technology Committee. Since 1997, Dr. McCormick has held the positions of Director of the University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and clinical care organization, as well as the position of Associate Dean of the UCSF School of Medicine. Additionally, since 1996, he has been a Fellow of the Royal Society, a society for science. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991, and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992, Dr. McCormick founded Onyx Pharmaceuticals (acquired by Amgen) and served as the company’s Chief Scientific Officer until 1996. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the United States at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund.
Stephanie Monaghan O’Brien
Stephanie Monaghan O’Brien has served as a member of our board of directors since 2011. Ms. O’Brien has been a member of the investment team at Morningside since 1997. She has served as a director for numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic focus, including oncology and immunotherapy, and has extensive experience providing operational and management oversight to venture-backed technology companies. She has also facilitated multiple financings for public and private companies such as Dendreon, BioVex, Stealth Biotherapeutics and Sohu.com. Prior to joining Morningside, Ms. O’Brien spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily on public offerings, venture capital finances and start-up companies. She previously worked at Chase Manhattan Bank, working in international portfolio analysis. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law.
Stephen A. Sherwin, M.D.
Stephen A. Sherwin, M.D., has served on our board of directors since 2015 and is a member of the board’s Science and Technology Committee. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. In addition to his advisory work with Aduro, Dr. Sherwin serves as a director of Biogen, Neurocrine Biosciences, and Rigel Pharmaceuticals and as a venture partner at Third Rock Ventures. He is also a member of the scientific steering committee of the Parker Institute for Cancer Immunotherapy. Dr. Sherwin holds a B.A. in Biology from Yale University, where he graduated summa cum laude, and an M.D. from Harvard Medical School. He is board-certified in internal medicine and medical oncology and a fellow of the American College of Physicians.